Guizhou Tiandi Medical Equipment Co., LTD

Welcome to the official website of Guizhou Tedia Medical Instruments Co. LTD!



Tedia Medical lnstruments Co., LTD

Guizhou Tedia Medical instruments Co., Ltd. is a modern production and operation enterprise integrating R & D, production and sales. It mainly produces disposable vacuum blood collection tubes (PET tubes, glass tubes and double-layer pet tubes) and other disposable medical experimental consumables.

MORE +

2016

company was founded

1800

The total investment is 18 million yuan

5000

Covering an area of 5000 square meters

Qualification Certificate

The pursuit of excellence, to build a world-class medical equipment company with international competitiveness

See our qualificatio





PRODUCT CENTER

NEWS CENTER

2021-08-24 Tedia Medical instruments and Xinpu District, Zunyi City Hospital of Traditional Chinese Medicine, Guizhou Province, China jointly carry out PRP promotion and exchange activities (including some examples)

This event focused on the use of PRP Tueb produced by Tedia Medical instruments Corporation to prepare PRP for subjects and the therapeutic effect.
MORE
12-09

2020

Medical device industry: implementation of high value consumables reform plan and improvement of industry standard

1、 Clear policy direction and time limit for completion Recently, the general office of the State Council issued the reform plan for the management of high value medical consumables. In the next 1-2 years, it will straighten out the price system of high value medical consumables, improve the whole process supervision and management of high value medical consumables, purify the market environment and medical service practice environment of high value medical consumables, and constantly regulate the high value medical consumables industry. The document focuses on improving the price formation mechanism and reducing the false high price of high-value medical consumables, including unifying the coding system and information platform, implementing the medical insurance access and dynamic adjustment of the catalog, improving the classified centralized procurement method, canceling the medical consumables bonus, and formulating the medical insurance payment policy. According to the policy plan, by the end of 2019, the first batch of key governance lists will be completed, centralized procurement of high-value medical consumables will be started, and the mark up of medical consumables will be cancelled. In 2020, the classification and coding of high-value medical consumables in national medical insurance will be formulated and unified, the price monitoring and centralized procurement management platform of high-value medical consumables will be established, the basic medical insurance access system of high-value medical consumables will be established, and the circulation management will be strengthened And so on. 2、 Consumables price is the trend, independent innovation can maintain the competitiveness of the company's products We believe that for high-value medical consumables, price reduction is the general trend, in line with the policy direction. Centralized procurement is a game among hospitals, product providers, distributors and distributors. The core point is still the product itself. If the product is highly standardized, with small differences and lack of innovation, it will face greater pressure of price reduction. However, for the distribution oriented enterprises, on the one hand, the distributors are the firewall of price reduction and bear the brunt of price reduction On the other hand, through R & D and innovation, enterprises can achieve product upgrading iteration, new and old alternation, seek new pricing for innovative products, and maintain the company's overall gross profit rate and net profit rate, which is also the direction of policy support. For new technology products, accelerate the registration and approval, and timely add them into the medical insurance catalog. Therefore, the price reduction of high-value medical consumables has a relatively small and moderate short-term impact on the manufacturers, and encourages more innovative enterprises. It is suggested to pay attention to enterprises with independent innovation products: Lepu medical, minimally invasive medical, etc. 3、 IVD does not fall within the scope of this policy IVD and medical imaging equipment belong to the cost of hospital, which is highly market-oriented and does not belong to the scope of the policy. Medical devices include high-value medical consumables, IVD, medical imaging equipment, etc. this policy refers to high-value medical consumables, excluding IVD and medical imaging equipment. IVD and medical imaging equipment belong to hospital cost, which is different from the charging mode of high-value consumables. Medical service charges, while medical insurance pays for medical service price, not directly for consumables price. The purchase of IVD and medical imaging equipment is not directly related to medical insurance, which is based on the needs of hospital departments, financial allocation and hospital income. It is suggested to pay attention to the enterprises that are less disturbed by the policy: Antu biological, aide biological, Mindray medical, Mike biological, Wanfu biological, etc.
MORE
12-09

2020

The medical device industry of economic development zone gets on the fast train

Recently, it was learned from the Municipal Drug Administration that the quality system verification time of innovative medical devices has been shortened from 30 working days to 6 working days. This is another major good news for accelerating the approval speed of innovative medical devices after the State Food and Drug Administration issued the special approval procedure for innovative medical devices. As the "Jingnan pharmaceutical Valley", Beijing Economic and Technological Development Zone will focus on promoting the approval and listing of innovative medical device R & D enterprises, and accelerate the improvement of medical device industry layout with innovative medical device R & D and production enterprises as the traction. Shorten the examination and approval process Speed up product launch "Medical devices should be submitted first, and the drug regulatory department should conduct preliminary examination, inspection and testing, quality system verification, production condition verification, production license issuance, and enterprise production and marketing," said the relevant person in charge of the Economic Development Zone Branch of the food and drug administration. This is the approval process for medical device enterprises to obtain the registration certificate and production license, and in the approval process, it is found that most of the medical devices R & D enterprises are not good at quality system construction, and often spend a lot of time in quality system verification. The quality system verification time of innovative medical devices in the city is shortened from 30 working days to 6 working days, which will greatly improve the speed of the whole approval process. To speed up the verification of the quality system of medical device registration and approval is the result of the implementation of the "service package" system of key enterprises and the overall simplification and optimization of the service process of product review and approval by the drug regulatory department in accordance with the requirements of the "action plan for further optimizing the business environment in Beijing (2018-2020)". For the headquarters of domestic and multinational pharmaceutical enterprises with high-end R & D and production capacity, the Municipal Drug regulatory department appointed leading cadres as "service housekeeper" and "attendant" to investigate and solve the actual difficulties of enterprises from the base construction, industrial development, product promotion, project financing, talent introduction and other aspects, and coordinate multi department integration of land planning, R & D investment, drug approval, financial industry To provide on-site information, policies and services for enterprises through policies and measures on work, project acceptance, public rental housing for talents, enrollment of employees' children, payment of talents rental subsidies, etc. In order to encourage pharmaceutical enterprises to develop and innovate drugs and medical devices with national and global influence, the Municipal Drug Administration Department creatively establishes and improves the "service package" system according to the characteristics of product registration and listing. The implementation of a special person responsible for one thing, one discussion, accurate docking, full guidance. Comprehensively reduce the time limit for review and approval, quality verification, product inspection and licensing, open up a green channel for the registration of innovative drugs and medical devices, and concentrate professional and technical forces to provide high-quality consulting services for enterprises. Under such precise service, the time for quality system verification of innovative drugs and medical devices in the city has been shortened from 30 working days to 6 working days, and the inspection time limit before product registration has been shortened by more than one third. The food and Drug Administration Economic Development Zone Branch is a pioneer in practicing the "Butler" service of medical device product review and approval. Under the implementation of the "service package" system in the economic and Technological Development Zone, the food and drug administration economic and Technological Development Zone Branch regularly held "quality system construction training meetings" for the key link of "quality system verification" in the approval of medical devices, to guide medical device R & D enterprises to build quality system in advance and prepare for product approval. The staff who supervise the R & D and production of medical device enterprises have also been transformed into the "intimate housekeeper" who guides the approval and listing of medical devices. In the process of supervision, they can understand the problems faced by enterprises, guide enterprises deeply, and solve problems for enterprises. In order to make the medical device ente
MORE
12-09

2020

FDA approved the first class II medical device software! Oleena helps cancer patients achieve self-management

Founded in 2001 and headquartered in Paris, volunts is a medical software development company. The company is committed to developing digital medical technology to improve the quality of medical services and reduce medical costs. Volunts was listed on the pan European stock exchange in May 2018 with the stock code vtx. Recently, volunts announced that its digital medical software oleena has been approved by FDA. The digital tool can help cancer patients achieve self-management. Voluntis has developed oleena based on its proprietary digital tumor treatment platform teraxiom oncology, aiming to provide services for cancer patients undergoing radiotherapy and chemotherapy, tumor immunotherapy and tumor targeted therapy by combining patient self-management and telemedicine monitoring. Oleena is the first FDA approved class II software-as-a-medical device, which can be used for a variety of cancer indications. The software can record the clinical symptoms and progress of patients in real time, and provide self-management suggestions for patients with diarrhea, pain, nausea and vomiting and other side effects of cancer treatment. At the same time, oleena also feeds back the recorded data to medical institutions, so that doctors can carry out remote monitoring and disease analysis. The software can provide patients with timely and efficient medical information to help them adjust the treatment plan. Voluntis leadership believes that helping patients achieve self-management can reduce the occurrence of unexpected situations such as treatment interruption and help improve the overall treatment effect of patients. Oleena, a treatment tool based on communication technology, enables patients to control the complicated symptoms during treatment, so as to play an active role in self-management. At the same time, the remote monitoring technology of digital medical tools will also help clinicians reduce the burden. In addition, volunts has developed other digital medical tools that can be used for remote monitoring of diabetes, such as insulia and diabeo, to help patients better control their symptoms and provide users with insulin dosage recommendations. "In addition to monitoring patients' symptoms, we believe that digital and personalized treatment can also help patients improve their condition in a timely manner and save costs for clinical medical services," said Pierre leurent, chief executive of voluntis. We are very happy to introduce oleena to cancer patients. This innovative oncology digital medical software will completely change the traditional cancer treatment methods. " Dr. Arvind dasari, an oncologist at UT MD Anderson Cancer Center of the University of Texas, said: "voluntis digital therapy based on oleena software can help patients realize self-management and actively intervene in patients' condition through simple language and system. This is undoubtedly an important milestone in the field of cancer treatment. "
MORE